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Background: Serrated adenomas (SAs) of the colorectum combine architectural features of hyperplas-
tic polyps and cytological features of classical adenomas. Molecular studies comparing SAs and clas-
sical adenomas suggest that each may be a distinct entity; in particular, it has been proposed that
microsatellite instability (MSI) distinguishes SAs from classical adenomas and that SAs and the
colorectal cancers arising from them develop along a pathway driven by low level microsatellite insta-
bility (MSI-L).
Aims: To define the molecular characteristics of SAs of the colorectum.
Materials and methods: We analysed 39 SAs from 27 patients, including eight SAs from patients
with familial adenomatous polyposis (FAP). We screened these polyps for selected molecular changes,
including loss of heterozygosity (LOH) close to APC (5q21) and CRAC1 (15q13-q22), MSI, and muta-
tions of K-ras, APC, p53, and β-catenin. Expression patterns of β-catenin, p53, MLH1, MSH2,
E-cadherin, and O6-methylguanine DNA methyltransferase (MGMT) were assessed by immunohisto-
chemistry. Comparative genomic hybridisation was performed on several polyps.
Results: MSI was rare (<5% cases) and there was no loss of expression of mismatch repair proteins.
Wnt pathway abnormalities (APC mutation/LOH, β-catenin mutation/nuclear expression) occurred in
11 SAs, including 6/31 (19%) non-FAP tumours. CRAC1 LOH occurred in 23% of tumours. K-ras muta-
tions and p53 mutations/overexpression were found in 15% and 8% of SAs, respectively. Loss of
MGMT expression occurred in 18% of polyps and showed a borderline association with K-ras muta-
tions. Aberrant E-cadherin expression was found in seven polyps. Comparative genomic hybridisation
detected no gains or deletions of chromosomal material.
Conclusions: The serrated pathway of colorectal tumorigenesis appears to be heterogeneous. In com-
mon with classical adenomas, some SAs develop along pathways involving changes in APC/β-catenin.
SAs rarely show MSI or any evidence of chromosomal-scale genetic instability. K-ras mutations may
however be less common in SAs than in classical adenomas. Some SAs may harbour changes in the
CRAC1 gene. Changes in known genes do not account for the growth of the majority of SAs.
Serrated adenomas (SAs), first described as a distinctentity by Longacre and Fenoglio-Preiser in 1990,1combine the architectural features of hyperplastic polyps
(glandular lumen serration) and the cytological features of
adenomas. Their prevalence at colonoscopy is 1–7%, with the
majority (54%) being found in the rectum and sigmoid
colon.1 2
The relationship between SAs, hyperplastic (metaplastic)
polyps, and classical (tubular, tubulovillous, and villous)
adenomas is not clear. Some evidence connects the classical
and serrated pathways: for example, SAs can occur in familial
adenomatous polyposis (FAP), individuals may have synchro-
nous or metachronous adenomas of both classical and
serrated types, and tumours may contain both classical and
serrated components.1 Molecular studies comparing SAs and
tubular adenomas have however suggested that they are
distinct entities, each with their own characteristic spectra of
molecular changes. Two studies have shown SAs to have a low
K-ras mutation rate compared with tubular adenomas,3 4
although this has not been confirmed in two other studies.5 6
Microsatellite instability (MSI) is another characteristic of
SAs that appears to distinguish them from tubular adenomas.
In one series, 53% of SAs showed MSI, mostly of the low level
(MSI-L) type.7 Very few sporadic classical adenomas show
MSI.8 p53 mutations, which are considered a late event in the
adenoma-carcinoma pathway, have been documented as
being as frequent as 47% in SAs.5 The high p53 mutation rate
and detection of significant dysplasia in 13–37% of SAs,9
10–15% having been shown to contain carcinomas in situ,3 has
led some to believe that SAs have a greater malignant poten-
tial than classical adenomas. However, not all molecular stud-
ies have shown consistent findings and earlier studies may
have been biased towards larger tumours which were more
likely to show dysplasia.10
Hyperplastic polyps have been considered non-neoplastic
and have not been thought to be associated with malignancy,
except in the hyperplastic polyposis syndrome. This is a rare
disease in which large hyperplastic polyps (>1 cm) are
distributed throughout the colon, and synchronous dysplasia
is common.11 Many of the polyps in this disease might there-
fore now be classified as SAs, and the condition provides evi-
dence for a hyperplastic polyp-SA sequence. Sporadic hyper-
plastic polyps are one of the commonest lesions in the large
bowel. They are smaller than SAs—two thirds are 5 mm or less
in diameter—and they are rarely greater then 1 cm.9 10 12–14
Recently, sporadic hyperplastic polyps have been shown to
exhibit some molecular changes, including K-ras mutation
(13–75%)4 5 and MSI-L (30%).7 Hyperplastic polyps also have
similar apomucin changes to SAs, expressing gastric mucin
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M1, MUC2, and reduced or absent MUC4.15 Many currently
believe that sporadic hyperplastic polyps should be regarded
as benign neoplastic lesions that may have a low malignant
potential.
It remains unclear therefore whether or not SAs, and
colorectal cancers arising from them, follow a different pathway
of tumorigenesis from most colorectal tumours. Jass and
colleagues6 proposed that the serrated pathway is driven by
MSI: the MSI-L hyperplastic polyp is the precursor lesion which
develops into MSI-L colorectal cancer through the intermediate
step of the MSI-L SA. Jass and colleagues have also found that
K-ras mutations are more frequent in certain MSI-L cancers
and that this may be due to silencing of O6-methylguanine DNA
methyltransferase (MGMT) expression by methylation.16
In this study, we have documented selected molecular
changes in a series of 39 SAs from the UK. We have assessed
MSI, loss of heterozygosity (LOH) close to APC (5q21) and on
15q13-q22 (the site of CRAC1, a novel colorectal adenoma and
carcinoma susceptibility gene17), and mutations of K-ras, APC,
p53, and β-catenin. Expression patterns of β-catenin, p53,
MLH1, MSH2, E-cadherin, and MGMT have been assessed
using immunohistochemistry. We have also performed com-
parative genomic hybridisation (CGH) on selected tumours in
order to search for additional genetic changes in SAs and to
test for the presence of chromosomal instability.
MATERIALS AND METHODS
SA samples were collected from St Marks Hospital.
Haematoxylin-eosin stained slides of each case were reviewed
by two histopathologists (AC and ICT) independently, to con-
firm the diagnosis and provide a consistent histological classi-
fication. All tumour material was archival, paraffin embedded
tissue. Five sections (10 µm) were cut from each tumour and
stained with toluidine blue. Each section was microdissected
by hand to remove the normal tissue, which was used as a
source of constitutional DNA. Wherever possible, DNA derived
from blood was also used as a source of constitutional DNA.
For mixed tumours of any type, the serrated adenomatous
component was microdissected, but due to the small size of
the tumours, it was impossible to exclude contamination of
the SA by either the adjacent hyperplastic or tubulovillous
component. Extraction of DNA from the tumour and normal
tissue was performed using the Qiagen (Hilden, Germany)
tissue extraction kit and from blood using standard methods.
For the LOH studies, polymorphic microsatellite markers in
the region of the APC gene (D5S82, D5S656, D5S489) and the
CRAC1 gene (D15S118, D15S1016, D15S1006, D15S1032) were
chosen from public databases (http://www.genethon.fr/ and
http://www.chlc.org/). MSI was assessed using the chromo-
some 5 and 15 markers and also D2S123 (dinucleotide),
D11S29 (dinucleotide), BAT26 (mononucleotide), MYCL
(mixed repeat), D15S659 (tetranucleotide), and D15S644
(tetranucleotide). Microsatellite loci were amplified in the
polymerase chain reaction (PCR) in a 25 µl volume, with one
oligonucleotide fluorescence labelled. The PCR reaction
typically contained 20–100 ng DNA, 50 mM KCl, 0.5–2.5 mM
MgCl2, 10 mM Tris-HCl, 0.1% Triton, 2.5 µg bovine serum
albumin, 0.2 mM of each dNTPs, 10 pmol of each oligonucle-
otide, and 1.25U Taq DNA polymerase (Promega, Madison,
Wisconsin, USA). The PCR reaction consisted of an initial step
of 94°C for four minutes, then 40 cycles of one minute at 94°C,
one minute at the appropriate annealing temperature, and one
minute at 72°C in a PTC-225 Peltier thermal cycler (MJ
Research, Waltham, Massachusetts, USA). Microsatellites
were analysed for LOH using the Genotyper programme (ABI,
Foster City, California, USA). LOH at each marker locus was
considered to be present if the area under one allelic peak in
the tumour was less than 0.5× or greater than 2× that of the
other allele, after correcting for the relative allelic areas using
the constitutional DNA. Tumours showing novel bands were
classed as MSI+. All PCR reactions were repeated on the same
sample and only changes consistent between the duplicated
reactions were scored as abnormalities.
Codons 12 and 13 of K-ras were amplified in the PCR using
previously published primers.5 The amplified product was then
directly sequenced in forward and reverse directions, using the
ABI sequencer and standard protocols.
Exons 5–8 of p53 were amplified in the PCR using
previously published primers5 18 and subjected to single
stranded conformational polymorphism (SSCP) analysis. The
amplified fragments (10 µl) were mixed with 10 µl of loading
buffer (98% deionised formamide, 10 mM EDTA, 0.025%
xylene cyanole FF, and bromophenol blue mixed in a ratio of
5:7 with 0.1% sodium dodecyl sulphate, 10 mM EDTA), heat
denatured at 95°C for 10 minutes and loaded onto an 8% non-
denaturing polyacrylamide midi-gel containing 10% glycerol.
Electrophoresis was carried out at a constant power of 6 W for
13–15 hours at room temperature. The gels were silver stained
using standard protocols. PCR and direct sequencing were
performed on those samples which showed a mobility shift or
extra banding on SSCP gels.
Regions G, H, and I of exon 15 of the APC gene
(corresponding to the mutation cluster region) were screened
for mutations using primers designed for archival material
which amplify 11 overlapping short fragments (details
available from the authors). Each sample was screened for
mutations using SSCP as above. For those samples which
showed a mobility shift or extra banding on SSCP gels, the
DNA fragment was reamplified and sequenced either directly
or after subcloning into plasmid pGEM-T-Easy.
Exon 3 of β-catenin was amplified in the PCR using the fol-
lowing primers: sense 5′-ATTTGATGGAGTTGGACATGGC-3′,
antisense 5′-CCAGCTACTTGTTCTTGAGTGAAGG-3′. SSCP
analysis was performed using the Phast System (Pharmacia,
Uppsala, Sweden). The PCR products were denatured at 95°C
for five minutes and subjected to electrophoresis on a 20%
precast polyacrylamide gel. DNA was detected by silver stain-
ing of gels using the standard Phast System protocol. PCR and
direct sequencing were performed on those samples which
showed a mobility shift or extra banding on SSCP gels.
For immunohistochemistry, serial sections (4 µm) were
deparaffinised, rehydrated, and incubated with the different
mouse monoclonal antibodies for one hour. Antigen retrieval
was used for β-catenin, MLH1, MSH2, E-cadherin, and MGMT
(pressure cooking two minutes at full pressure in 3 litres of
0.01 M citrate buffer). Dilutions were 1 in 70 for p53
(Oncogene Science), 1 in 800 for β-catenin (Transduction
Laboratories, San Diego, California, USA), 1 in 100 for MLH1
(Pharmingen, San Diego, California, USA), 1 in 100 for MSH2
(Calbiochem, San Diego, California, USA), 1 in 20 for
E-cadherin (ICRF), and 1 in 50 for MGMT (Neomarkers, Lab
Vision Corporation, Fremont, California, USA). Biotinylated
rabbit antimouse immunoglobulin diluted 1 in 400 in 3% nor-
mal human serum was used as the secondary antibody. After
washing, the slides were incubated in peroxidase conjugated
streptavidin-biotin complex (Dako, Copenhagen, Denmark)
for 30 minutes. The peroxidase was demonstrated by incubat-
ing in diaminobenzidine solution for five minutes. After rins-
ing in water, nuclei were lightly counterstained with
haematoxylin for two minutes and coverslipped. The sections
were then scored by a histopathologist (AH or MJA) for pres-
ence, location, and intensity of staining (3, strong; 2,
moderate; 1, weak; 0, no staining).
CGH was performed on four tumours. Tumour and control
DNAs were labelled by nick translation and hybridised to nor-
mal female metaphase spreads in the presence of human CotI
DNA using standard protocols.19 Metaphase chromosome
preparations were captured using Smartcapture software
(Vysis). Five to 10 representative images were analysed using
Quips CGH software (Vysis).
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RESULTS
In this series of 39 SAs, the majority (25/39, 64%) showed mild
dysplasia (table 1, fig 1); 11 tumours (28%) showed moderate
dysplasia and three (8%) showed severe dysplasia. One
tumour (No 30) contained both SA and carcinoma. There were
four mixed tubulovillous/SAs (Nos 2, 19, 24, 36) and three
mixed hyperplastic polyps/SAs (Nos 1, 14, 25). The majority of
cases (79%) were from the distal colon or rectum and the
average maximum diameter was 0.9 cm. Eight tumours came
from five patients with FAP. A further 14 patients were known
Table 1 Summary of clinicopathological data
Patient Sample Histology Dysplasia Site Size (cm) Previous history
i 1 Mixed HPP/SA Mild Rectum 0.2 Multiple HPPs and TVAs
ii 2 Mixed TVA/SA Mild Rectum 0.7 FAP
iii 3 SA Mild Transverse colon 0.6 Multiple TVAs and CRC
iv 4 SA Mild SU 0.5 FAP
v 5 SA Mild SU 0.6 FAP
vi 6 SA Mild Sigmoid 0.8 CRC
vii 7 SA Mild Sigmoid 0.1 TVA
x 8 SA Mild Sigmoid 0.4 Multiple HPPs and TVAs
xviii 9 SA Moderate Rectum 2.0 NK
viii 10 SA Mild SU 1.3 NK
xix 11 SA Mild Rectum 0.4 Multiple HPPs and TVAs
iii 12 SA Mild Ascending colon 0.5 Multiple TVAs and CRC
ix 13 SA Mild Rectum 1.2 FAP
xxvii 14 Mixed HPP/SA Mild Transverse colon 0.2 Multiple HPPs and TVAs
v 15 SA Moderate SU 0.3 FAP
v 16 SA Moderate SU 0.7 FAP
v 17 SA Moderate SU 0.4 FAP
vi 18 SA Mild Rectum 0.6 CRC
xx 19 Mixed TVA/SA Mild Sigmoid 0.6 UC
xi 20 SA Mild SU 0.7 NK
xxvii 21 SA Mild Ascending colon 0.9 Multiple HPPs and TVAs
xi 22 SA Mild Rectum 0.8 NK
xii 23 SA Moderate SU 1.5 FAP
xxv 24 Mixed TVA/SA Mild Sigmoid 0.2 Multiple HPPs and TVAs
x 25 Mixed HPP/SA Mild Sigmoid 0.7 Multiple HPPs and TVAs
xiii 26 SA Mild SU 0.8 CRC
xiv 27 SA Moderate SU 0.2 Multiple HPPs and TVAs
xiv 28 SA Moderate SU 0.5 Multiple HPPs and TVAs
xxi 29 SA Severe Rectum 3.8 Multiple TVAs
xxii 30 SA/Carcinoma Severe Rectum 3.2 Multiple TVAs
xv 31 SA Severe Rectum 0.4 CRC
xxvi 32 SA Mild Caecum 0.5 Multiple HPPs and TVAs
xxiii 33 SA Moderate Hepatic flexure 0.8 Multiple TVAs
xvi 34 SA Moderate Rectum 1.4 Multiple HPPs
xvii 35 SA Mild Descending colon 1.0 Multiple TVAs
xvii 36 Mixed TVA/SA Moderate Descending colon 1.0 Multiple TVAs
xvii 37 SA Moderate Descending colon 0.5 Multiple TVAs
xxiv 38 SA Mild Rectum 1.5 TVA and SA
xxv 39 SA Mild Rectum 0.2 Multiple HPPs and TVAs
SA, serrated adenoma; TVA, tubulovillous adenoma; HPP, hyperplastic polyp; SU, site undefined; CRC, colorectal carcinoma; FAP, familial adenomatous
polyposis; UC, ulcerative colitis; NK, not known.
Size, maximum diameter.
Figure 1 (A) Case No 13—serrated
adenoma with mild dysplasia. (B)
Case No 6—serrated adenoma with
mild dysplasia.
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to have had a history of sporadic classical adenomas, and of
those, seven had also had previous hyperplastic polyps.
Two tumours (5%) showed MSI-L (fig 2A), one at MYCL
only (No 37) and one at D15S118 only (No 3). In both cases, a
single repeat unit bandshift was observed. None of the
tumours showed MSI at D2S123, D11S29, BAT26, or at the
other markers used. No loss or other abnormality of MLH1 or
MSH2 staining was found in any of the tumours.
Thirty samples were available for LOH analysis, the remain-
ing nine samples having no source of paired normal DNA. Two
tumours (Nos 7, 32) showed LOH of at least one marker in the
region of APC (fig 2B). Neither of these tumours was from an
FAP patient and in neither was a truncating APC mutation
subsequently found. Somatic mutations in the mutation clus-
ter region of the APC gene (fig 3A, table 2) were found in five
tumours (13%); one of these tumours was a mixed
tubulovillous/SA but the rest were pure SAs. Four of the five
tumours with somatic APC mutations were from FAP patients.
One codon 33 β-catenin mutation was found in a tumour (No
31) with severe dysplasia and abnormal (cytoplasmic)
β-catenin expression on immunohistochemistry (fig 3B). Five
tumours showed nuclear β-catenin staining; in three cases
this was focal and in the others widespread (table 2). Two of
the polyps (Nos 4 and 13) with nuclear β-catenin staining
came from FAP patients, and another (No 7) showed LOH at
APC.
Seven of 30 tumours (23%) showed LOH on 15q in the
region of the CRAC1 gene (table 2), three at D15S016, two at
D15S644, one at D15S1006, and one at D15S118. Six tumours
(15%) showed mutation of K-ras, five at codon 12 and one at
codon 13 (table 2).
Two tumours (5%) were found to have p53 mutations, both
in exon 5: one mutation occurred in the sample with
associated carcinoma (No 30) which also had nuclear p53
staining on immunohistochemistry and the other mutation
occurred in the mixed tubulovillous/SA (No 2) which had
normal p53 immunohistochemistry. One other tumour (No
15) showed abnormal expression of p53 but had no detectable
p53 mutation.
Loss of expression of MGMT occurred in seven tumours
(table 2), of which three had mutations in K-ras. There was a
borderline association between loss of MGMT expression and
K-ras mutation (p=0.06, Fisher’s exact test). Three tumours
showed reduced membrane expression of E-cadherin and four
strong cytoplasmic staining with E-cadherin (table 2).
Comparative genomic hybridisation was performed on
samples Nos 15, 30, 38, and 39. No chromosomal-scale imbal-
ances were found in any tumour.
DISCUSSION
The serrated pathway of colorectal tumorigenesis appears to
be heterogeneous, with both similarities to and differences
from the “classical” pathway. The first point of similarity is the
low level of MSI in both types of lesion. In our study, only two
SAs showed MSI-L despite our use of multiple markers of dif-
ferent types, and no tumour showed loss of mismatch repair
proteins. The reasons for these difference between our study
and others7 are unclear because similar microsatellite markers
were used to assess the tumours. One reason may be
differences in the tumours studied. Previous series have
shown high level microsatellite instability (MSI-H) to be
infrequent in sporadic serrated polyps (in contrast with
serrated polyps from patients with hyperplastic polyposis20)
and where MSI-H does occur it appears more frequently in
proximal tumours. MSI-H was found in 17% (5/29) of cases by
Jass and colleagues.20 These polyps were proximal and mixed
serrated/hyperplastic. Hiyama and colleagues5 found only 1/19
SAs to be MSI-H. In a recent study by Makinnen et al, eight of
the 27 carcinomas associated with SAs were analysed for MSI
and in three cases (37.5%), all proximal, MSI was found.21 We
have also found that repeating the PCR amplification where
the reaction contains small amounts of target DNA of poten-
tially low quality can be important in determining true MSI.
Figure 2 (A) Low level microsatellite instability in sample No 37
using marker MYCL. (B) Loss of heterozygosity at D5S656 in sample
No 7.
Normal
Tumour Normal
Tumour
178
178 182 Size (bp)
A B
Figure 3 (A) 5 base pair deletion at
codon 1309 of the APC gene in
sample No 15. (B) β-catenin mutation
codon 33 (TCT→TGT) in sample No
31.
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Table 2 Summary of molecular data
Patient Tumour MSI APC LOH APC mutation Beta-catenin mutation
Beta-catenin
IHC CRAC1 LOH K-ras mutation p53 mutation p53 IHC
E-cadherin
IHC MGMT IHC
i 1 D15S1016 Reduced
ii 2* Codon 1478, Del1bp D15S644 Codon 184, GAT→CAT
iii 3 D15S118 D15S1006
iv 4* Focal nuclear
v 5*
vi 6 D15S644
vii 7 D5S656 Focal nuclear D15S1016
x 8
xviii 9†
viii 10
xix 11†
iii 12 D15S118
ix 13* Codon 1556, Del 1bp Focal nuclear Nuclear
xxvii 14†
v 15* Codon 1309, Del 5bp
v 16*
v 17*
vi 18 D15S1016
xx 19†
xi 20 Reduced Lost
xxvii 21†
xi 22 Reduced
xii 23* Codon 1465, Del 2bp Codon 12 GGT→GAT Lost
xxv 24 Codon 12 GGT→GCT
x 25
xiii 26
xiv 27 Codon 1411, Del 1bp Cytoplasmic Lost
xiv 28 Cytoplasmic Lost
xxi 29† Codon 12 GGT→GAT Lost
xxii 30† Nuclear Codon 175, CGC→CAC Nuclear Lost
xv 31 Codon 33, TCT→TGT Cytoplasmic Codon 12 GGT→GCT
xxvi 32 D5S82
xxiii 33† Codon 12 GGT→GAT Lost
xvi 34 Nuclear Codon 13, GGC→GAC
xvii 35
xvii 36 Cytoplasmic
xvii 37 MYCL Cytoplasmic
xxiv 38†
xxv 39
LOH, loss of heterozygosity; MSI, microsatellite instability; IHC, immunohistochemistry.
*FAP patient.
†No normal available for MSI/LOH.
Note that all APC mutations are somatic, germline changes either having been detected occurring outside the region screened or having been excluded from this region.
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In the first PCR, 12 samples appeared to show MSI (four at
D2S123, two at D11S29, one at D15S118, one at D15S644, and
four at MYCL). All of these showed a single extra discrete band
in tumour DNA. No sample showed a marked alteration in
repeat length appearing as a ladder. On repeating the PCR for
these samples, apart from the two tumours with instability of
MYCL and D15S118, none of these additional bands was
present, suggesting that they were artefacts. Detection of MSI
can therefore be problematic in DNA extracted from paraffin
embedded tissue and its prevalence may have been overesti-
mated. MYCL may however be a relatively sensitive and
specific marker for MSI, as Jass et al have reported.22
In common with the majority of classical adenomas, a
minority of SAs in our series developed along pathways
involving changes in APC/β-catenin. In our series, eight SAs
came from patients with FAP and six other SAs had
alterations in APC and/or β-catenin (table 2). This association
has been noted previously,1 but despite this, many studies on
SAs have not looked at APC directly but have used 5q21 LOH
or nuclear β-catenin staining to infer APC mutation. Our study
shows that APC mutations in SAs can occur in the absence of
LOH and/or nuclear β-catenin staining, as previous studies
have shown for classical adenomas.23 24 All studies that have
looked for APC mutations in SAs outside FAP have shown a
low rate of detection4 25 relative to the 30–64% reported in
classical adenomas (for example, see Miyaki and colleagues24
and Morris and colleagues26). However, plentiful high quality
DNA has been used in many of the studies of classical adeno-
mas in contrast with the much more limited analysis which is
possible using the archival material analysed here. We cannot
therefore exclude the possibility that APC mutations are
involved in the pathogenesis of a much greater proportion of
SAs than we have found.
p53 mutations or aberrant expression occurred in fewer
than 10% of our SAs compared with 47% in one previous
study.5 This difference is likely to reflect the fact that the
majority of tumours in our series showed only mild dysplasia.
p53 mutations are also uncommon in early adenomas of clas-
sical morphology. A further point of similarity between SAs
and classical adenomas is the absence of chromosomal-scale
genetic instability, as assessed using CGH (for example, see
Barletta and colleagues27).
Our data also suggest some differences between SAs and
classical adenomas. The finding of LOH at CRAC1 in 23% of
SAs is intriguing given the presence of both serrated and clas-
sical adenomas in families with germline CRAC1 mutations.17
However, these data require confirmation once the position of
CRAC1 has been refined and some caution also as individual
markers only were lost. Our preliminary data suggest that
LOH at CRAC1 occurs in fewer than 15% of classical adenomas
(Jaeger et al, unpublished observations).
K-ras mutations occurred in about 15% of our tumours. The
detection method for K-ras mutations was designed to be
sensitive. There were few K-ras mutations in this study com-
pared with published series of sporadic classical adenomas
(44%), suggesting that this may be a true difference between
the two types of adenoma.5 26 The fact that K-ras mutations
were more common in tumours with loss of MGMT expression
supports some of the findings of Whitehall and colleagues,16
but unlike their study, MGMT loss did not occur in our
tumours which showed MSI-L.
Our study suggests that APC and other Wnt pathway
abnormalities may be important in the pathogenesis of a sub-
set of SAs of the colorectum as well as in classical adenomas.
The CRAC1 gene may also be involved in serrated tumorigen-
esis. Contrary to previous data, MSI was rare in sporadic and
FAP associated SAs and p53 abnormalities were uncommon,
at least in the absence of moderate or severe dysplasia. In
accordance with previous studies, we found that K-ras muta-
tions were less frequent in SAs than classical adenomas. The
differences between our study and previous ones may reflect
different populations—many of the molecular studies on SAs
have been performed on Japanese cases5 7 10 28—and the
increasing recognition by histopathologists of more subtle
manifestations of the serrated phenotype.
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